Skip to main content
. 2022 Jul 19;13:946318. doi: 10.3389/fimmu.2022.946318

Figure 1.

Figure 1

Neutralizing antibody titers against an ancestral wildtype (WT) strain and three variants of concern (Delta, Omicron BA.1, and Omicron BA.2) in post-vaccination and post-infection serum samples. (A) Serum samples from individuals who had received three doses of an mRNA vaccine collected one month and three months after the last vaccination (n=15). (B) Serum samples from individuals who were infected with a WT strain, followed by three doses of an mRNA vaccine collected three weeks after the last vaccination (n=9). (C) Serum samples from individuals who were infected with a WT strain collected three weeks and seven months after infection (n=11). (D) Serum samples obtained from individuals who had a primary infection with Omicron BA.1 collected one month after infection (n=22). (E) Serum samples obtained from individuals who had a primary infection with Omicron BA.2 collected one month after infection (n=21). (F) Serum samples from individuals who were infected with an Omicron variant and had previously been vaccinated collected one month after infection (Omicron breakthrough infections, n=43). Horizontal dotted lines show the cut-off, dots individual sera, and red lines median titers. Black asterisks indicate significant differences to WT (D614G). The Kruskal-Wallis test with Dunn’s post-hoc test was used for significance testing (*, p < 0.05; **, p < 0.01; ***, p <0.001; ****, p < 0.0001). Significant differences between Omicron BA.1 and BA.2 neutralization titers are indicated by red asterisks (Mann-Whitney test; ***, p < 0.001). WT, wildtype strain (B.1.1) with the D614G substitution; Delta, Delta VOC (B.1.617.2-like, sub-lineage AY.122); O_BA.1, Omicron (B.1.1.529) sub-lineage BA.1 VOC; O_BA.2, Omicron sub-lineage BA.2 VOC; NT, neutralization test.